Egypt · Delayed Price · Currency is EGP GlaxoSmithKline S.A.E Statistics
Total Valuation
EGX:BIOC has a market cap or net worth of EGP 5.46 billion. The enterprise value is 5.06 billion.
| Market Cap | 5.46B |
| Enterprise Value | 5.06B |
Important Dates
The next estimated earnings date is Monday, May 18, 2026.
| Earnings Date | May 18, 2026 |
| Ex-Dividend Date | Jan 12, 2026 |
Share Statistics
EGX:BIOC has 83.51 million shares outstanding.
| Current Share Class | 83.51M |
| Shares Outstanding | 83.51M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.75% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 2.43M |
Valuation Ratios
The trailing PE ratio is 25.61.
| PE Ratio | 25.61 |
| Forward PE | n/a |
| PS Ratio | 1.46 |
| PB Ratio | 2.46 |
| P/TBV Ratio | 2.46 |
| P/FCF Ratio | 85.92 |
| P/OCF Ratio | 22.67 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.15, with an EV/FCF ratio of 79.66.
| EV / Earnings | 23.74 |
| EV / Sales | 1.36 |
| EV / EBITDA | 16.15 |
| EV / EBIT | 20.10 |
| EV / FCF | 79.66 |
Financial Position
The company has a current ratio of 1.62, with a Debt / Equity ratio of 0.04.
| Current Ratio | 1.62 |
| Quick Ratio | 0.57 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.29 |
| Debt / FCF | 1.29 |
| Interest Coverage | 18.65 |
Financial Efficiency
Return on equity (ROE) is 10.12% and return on invested capital (ROIC) is 5.94%.
| Return on Equity (ROE) | 10.12% |
| Return on Assets (ROA) | 3.32% |
| Return on Invested Capital (ROIC) | 5.94% |
| Return on Capital Employed (ROCE) | 9.46% |
| Weighted Average Cost of Capital (WACC) | 8.46% |
| Revenue Per Employee | 4.66M |
| Profits Per Employee | 266,533 |
| Employee Count | 800 |
| Asset Turnover | 0.92 |
| Inventory Turnover | 2.58 |
Taxes
In the past 12 months, EGX:BIOC has paid 112.24 million in taxes.
| Income Tax | 112.24M |
| Effective Tax Rate | 34.49% |
Stock Price Statistics
The stock price has increased by +74.58% in the last 52 weeks. The beta is 0.76, so EGX:BIOC's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | +74.58% |
| 50-Day Moving Average | 62.70 |
| 200-Day Moving Average | 60.15 |
| Relative Strength Index (RSI) | 59.54 |
| Average Volume (20 Days) | 89,310 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, EGX:BIOC had revenue of EGP 3.73 billion and earned 213.23 million in profits. Earnings per share was 2.55.
| Revenue | 3.73B |
| Gross Profit | 679.77M |
| Operating Income | 216.65M |
| Pretax Income | 325.48M |
| Net Income | 213.23M |
| EBITDA | 265.13M |
| EBIT | 216.65M |
| Earnings Per Share (EPS) | 2.55 |
Balance Sheet
The company has 479.69 million in cash and 81.76 million in debt, with a net cash position of 397.93 million or 4.76 per share.
| Cash & Cash Equivalents | 479.69M |
| Total Debt | 81.76M |
| Net Cash | 397.93M |
| Net Cash Per Share | 4.76 |
| Equity (Book Value) | 2.22B |
| Book Value Per Share | 26.54 |
| Working Capital | 1.38B |
Cash Flow
In the last 12 months, operating cash flow was 240.83 million and capital expenditures -177.28 million, giving a free cash flow of 63.55 million.
| Operating Cash Flow | 240.83M |
| Capital Expenditures | -177.28M |
| Depreciation & Amortization | 48.48M |
| Net Borrowing | -43.06M |
| Free Cash Flow | 63.55M |
| FCF Per Share | 0.76 |
Margins
Gross margin is 18.22%, with operating and profit margins of 5.81% and 5.72%.
| Gross Margin | 18.22% |
| Operating Margin | 5.81% |
| Pretax Margin | 8.72% |
| Profit Margin | 5.72% |
| EBITDA Margin | 7.11% |
| EBIT Margin | 5.81% |
| FCF Margin | 1.70% |
Dividends & Yields
This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 1.53%.
| Dividend Per Share | 1.00 |
| Dividend Yield | 1.53% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 6.63% |
| Buyback Yield | n/a |
| Shareholder Yield | 1.53% |
| Earnings Yield | 3.91% |
| FCF Yield | 1.16% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
EGX:BIOC has an Altman Z-Score of 2.86 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.86 |
| Piotroski F-Score | 5 |